Clinical Trial News

Brain+ starts clinical trial of BrainBlossom, its next-gen cognitive training tech for Mild Cognitive Impairment (MCI), in collaboration with Aalborg University Hospital. The trial aims to test the feasibility and impact of BrainBlossom as a home-delivered treatment for MCI, with results expected in early 2025. Success could lead to a larger trial for regulatory data and a partnership for commercialization.

Crestone announces positive Phase 2 trial results for CRS3123 in treating C. difficile infections, showing high clinical cure rates, low recurrence, and safety. NIAID funds $4.5 million for further studies.

A Middle Tennessee neurology office is conducting clinical trials for a potentially groundbreaking Alzheimer’s drug, BenfoTeam, which uses a lab-made version of vitamin B1 to possibly slow down or reverse the disease. The trial, focusing on cognitive function and daily routine activities, is open to people aged 50-89 with mild memory concerns or mild Alzheimer’s, not in long-term nursing care, and willing to participate in an 18-month program.

A 59-year-old metastatic breast cancer patient experienced rapid symptom improvement with HT-001 therapy, discontinuing treatment after one week. HT-001, developed by Hoth Therapeutics, shows promise for managing EGFRI-associated skin toxicities, enhancing patient quality of life without interrupting cancer therapy.

A recent study highlights the benefits of using blinatumomab as a third consolidation course before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk, first-relapse B-cell acute lymphoblastic leukemia (B-ALL). The study found that blinatumomab significantly improves overall and event-free survival compared to standard chemotherapy, regardless of the conditioning regimen used.

Evommune initiated a Phase II trial of EVO756 to treat chronic inducible urticaria (CIndU) in adults, aiming to assess safety and efficacy in 30 patients with symptomatic dermographism or cold urticaria. The trial uses disease-specific provocation thresholds to measure treatment response, with patients receiving EVO756 orally once daily for four weeks. EVO756, a selective MRGPRX2 antagonist, could offer a new oral treatment for mast cell-mediated diseases and rapidly alleviate itching.

A $3 million NIH-funded study led by Marzieh Salehi, MD, MS, at UT Health San Antonio investigates the antidiabetic and anti-obesity effects of semaglutide in people with spinal cord injury, aiming to impact treatment guidelines and understand underlying diabetes mechanisms in this population.

Emapalumab improves stem cell transplant outcomes for children with hemophagocytic lymphohistiocytosis (HLH), reducing mixed chimerism and enhancing intervention-free survival, according to a study published in the journal Blood.

Clinical trial finds adding anti-clotting drugs to stroke care ineffective; medications did not improve patients’ outcomes, as indicated in The New England Journal of Medicine.

Axsome Therapeutics announces FDA acceptance of NDA resubmission for AXS-07, a novel oral medicine for acute migraine treatment, with a PDUFA goal date of January 31, 2025.